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Summary Anastrozole is the first aromatase inhibitor to show a significant survival advantage over megestrol acetate in post-menopausal
women with advanced breast cancer. The rationale for extending the use of aromatase inhibitors to the treatment of early breast cancer is
based on the efficacy observed in the advanced setting, combined with good tolerability and a convenient dosing regimen. Furthermore,
oestrogen deprivation by ovarian ablation (similar to oestrogen antagonism with tamoxifen) is already established as an effective adjuvant
treatment in premenopausal women with modality breast cancer. Anastrozole produces a profound suppression of plasma oestrogen levels
which is greater than that obtained with earlier aromatase inhibitors (formestane, aminoglutethimide) or megestrol acetate. This could account
for the differences in clinical efficacy seen between anastrozole and megestrol acetate. In terms of benefits over other endocrine agents,
anastrozole causes significantly less weight gain than megestrol acetate; it does not have the partial agonist activity of tamoxifen, and is
unlikely to lead to tumour stimulation in patients resistant to tamoxifen or to exert proliferative effects on the endometrium. The lack of
oestrogen agonist activity, however, may possibly have detrimental effects on bone mineral density and blood lipid profile. Current clinical
trials are investigating the efficacy and safety of anastrozole in the early breast cancer setting. The results of these trials will help to determine
whether anastrozole has any benefits over tamoxifen, the current treatment of choice in post-menopausal women with early breast cancer.
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The introduction ofthe new generation ofnon-steroidal aromatase
inhibitors, as typified by anastrozole, presents an exciting opportu-
nity in the treatment of breast cancer. These agents provide selec-
tive (i.e. they do not interact with other enzymes involved in
adrenal steroid synthesis) and potent inhibition of the enzyme
aromatase (Yates et al, 1996), with a subsequent profound suppres-
sion of plasma oestrogens. These properties are combined with
good tolerability and a convenient, once-daily dosing regimen
(Buzdar et al, 1996a). The new aromatase inhibitors may have
improved efficacy compared with the standard, second-line
endocrine therapies, megestrol acetate and aminoglutethimide.
Anastrozole is the first aromatase inhibitor to show a significant
survival advantage over megestrol acetate in post-menopausal
women with advanced breast cancer who have failed on prior
tamoxifen treatment (Roseman et al, 1997). In an overview
analysis of two prospective, randomized, phase III trials (Jonat
et al, 1995, 1996; Buzdar et al, 1996a; Budzar et al, 1997), anas-
trozole increased the median survival time from 22.5 months (with
megestrol acetate) to 26.7 months (P = 0.02) and the 2-year
survival rate from 46.3% to 56.1% at a median follow-up duration
of 31 months (Roseman et al, 1997). The finding that adjuvant
therapy (ovariectomy or tamoxifen treatment) may 'cure' early
breast cancer but not advanced disease (despite objective tumour
responses) suggests that even modest differences in the effects of
drugs used in advanced disease could translate into a real survival
benefit in the adjuvant setting.
Anastrozole is the first endocrine agent since tamoxifen to enter
large-scale clinical trials of adjuvant therapy in post-menopausal
women. This paper describes the rationale for the use ofaromatase
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inhibitors in the adjuvant setting and gives a brief overview ofthe
clinical trials programme.
RATIONALE FOR ADJUVANT USE OF
AROMATASE INHIBITORS
The rationale for extending the use of aromatase inhibitors to the
treatment of early breast cancer in post-menopausal women is
based on several considerations.
Mechanism of action
Oestrogen deprivation by ovarian ablation is already established as
an effective adjuvant treatment in premenopausal women. The
beneficial effect of oestrogen antagonism in the treatment of early
breast cancer in post-menopausal women has been clearly demon-
strated for tamoxifen, which currently may be regarded as the 'gold
standard' in this patient population (Early Breast Cancer Trialists'
Collaborative Group, 1992). It is therefore possible that oestrogen
deprivation through aromatase inhibition could be advantageous in
the early breast cancer setting. Indeed, the new-generation
aromatase inhibitors have demonstrated superior efficacy compared
to conventional therapy for advanced disease (Roseman et al, 1997).
The new-generation aromatase inhibitors produce profound
suppression ofoestrogen concentrations. With anastrozole, consis-
tency has been shown between the inhibition of whole-body
aromatase activity and the suppression of plasma oestrogen levels
down to the limits of detection of the assays used (Table I)
(Geisler et al, 1996a). The earlier aromatase inhibitors amino-
glutethimide (MacNeill et al, 1992) and formestane (Jones et al,
1992) provided high levels of aromatase inhibition (although less
than those of anastrozole), but not suppression of plasma
oestrogen levels to a similar extent (L0nning, 1996).
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Table 1 Suppression of aromatase activity and plasma oestrogen levels in
10 patients progressing after tamoxifen treatment during treatment with
anastrozole (data from Geisler et al, 1996a)
Mean suppression (%)
Anastrozole, 1 mg Anastrozole, 10 mg
Aromatase activity 96.7 98.1
Plasma oestrone level 86.8 86.1
Plasma oestradiol level 84.0 83.5
















Megestrol acetate, 4x40 mg (n=85)
Anastrozole, 10 mg (n =92)
Anastrozole, 1 mg (n=98)
1 2 3 4 5 6 7 8 9
Months from start oftherapy
Data from earlier trials evaluating plasma oestrogen suppression
with first- and second-generation aromatase inhibitors may not be
directly comparable with contemporary results because of the
different radioimmunoassays used. More recent assays, despite
showing a somewhat better oestrogen suppression, have shown
both aminoglutethimide and formestane to be clearly inferior to
anastrozole in terms ofhormone suppression (Geisler et al, 1996b,
1997). Furthermore, megestrol acetate, which might also function
as an oestrogen suppressor, reduced plasma oestrogen levels to a
markedly smaller degree than anastrozole (Lundgren et al, 1996). It
could be speculated, therefore, that the differences in oestrogen
suppression between anastrozole and megestrol acetate account for
the differences in clinical efficacy ofthese two endocrine agents.
Tolerability
New-generation aromatase inhibitors, such as anastrozole, have
good tolerability profiles (Buzdar et al, 1996a). This is in marked
contrast to the first-generation aromatase inhibitor, amino-
glutethimide, which is too toxic for adjuvant use (Coombes et al,
1987). In addition, the progestin, megestrol acetate, is poorly toler-
ated in the treatment ofearly disease (Pannuti et al, 1988), a finding
consistent with its less favourable tolerability compared with new-
generation aromatase inhibitors in the treatment ofadvanced disease
(Buzdar et al, 1996a; Dombemowsky et al, 1998). One major disad-
vantage associated with megestrol acetate is weight gain; however,
this occurs in significantly fewer patients with advanced breast
cancer treated with anastrozole. In one study, 12% ofpatients treated
with megestrol acetate experienced weight gain of over 10%
compared with 4% of patients treated with anastrozole, 10 mg
(P = 0.002), and only 2% ofpatients treated with anastrozole, 1 mg
(P = 0.0001) (Buzdar et al, 1996a). Moreover, patients who receive
megestrol acetate continue to gain weight over time (Figure 1). The
improved tolerability of anastrozole compared with megestrol
acetate has been confirmed over a longer exposure time of 12
months in post-menopausal women with advanced breast cancer
(Buzdaret al, 1996b). This is important in the adjuvant setting where
the need for long-term treatment has been established with tamox-
ifen, which is significantly more effective when given for 5 years
compared with 2 years (Current Trials Working Party ofthe Cancer
Research Campaign Breast Cancer Trials Group, 1996; Fisher et al,
1996; Swedish Breast Cancer Cooperative Group, 1996).
Adverse events
Based on its mechanism ofaction, anastrozole would notbeexpected
to exhibit the partial agonist activity associated with anti-oestrogens,
such as tamoxifen (Yates et al, 1996). Although anastrozole's
Figure 1 Weight gain over time in post-menopausal patients with advanced
breast cancer treated with anastrozole, 1 mg or 10 mg once daily, or
megestrol acetate, 40 mg four times daily. s.e.m., standard error mean.
Reproduced with permission from Buzdar et al, 1996a
efficacy may be equivalent to that of tamoxifen in the adjuvant
setting, the aromatase inhibitor is unlikely to lead to tumour stimula-
tion in tamoxifen-resistant individuals. Similarly, it is unlikely that
anastrozole hasproliferative effects on theendometrium. Conversely,
however, it is alsoimportant to bearin mind the possible detrimental
effect this lack of oestrogen agonist activity may have on bone
mineral density and blood lipid profile. These possible effects of
anastrozole in the adjuvant setting are being investigated in sub-
protocols ofthe current clinical trials programme.
CURRENT CLINICAL TRIALS OF ANASTROZOLE
The future role of new-generation aromatase inhibitors in post-
menopausal early breast cancer will ultimately be determined by
the outcome of a programme of prospective clinical trials. Other
novel aromatase inhibitors, such as letrozole and exemestane, are
also to be evaluated in the adjuvant setting. The anastrozole trials
are designed to compare the aromatase inhibitor as monotherapy
with tamoxifen, in combination with tamoxifen and in sequential
treatment with tamoxifen. Evidence from experiments in the rat
using a chemically induced tumour model suggests that treatment
with tamoxifen plus an aromatase inhibitor may be superior to
tamoxifen therapy alone (Tominaga et al, 1990; Zaccheo et al,
1993). It may also be possible to take advantage of anastrozole's
lack of cross-resistance with other endocrine agents, seen during
the treatment of advanced disease, so that sequential therapy can
be extended into the adjuvant setting.
Arimidex, Tamoxifen Alone or in Combination (ATAC)
trial
The ATAC trial has been designed to compare 5 years oftamoxifen
(Nolvadex) alone with anastrozole (Arimidex) monotherapy and
with tamoxifen plus anastrozole as adjuvant treatment in post-
menopausal women withearly breast cancer(Figure 2) (Baum etal,
1998). The main assessments are time to breast cancer recurrence,
overall survival andtolerability. It will be interesting to see whether
the superiority of the aromatase inhibitor-tamoxifen combination
over tamoxifen alone in the rat tumour model translates into the
clinical setting (Zaccheo et al, 1993; Tominaga et al, 1990).
Although clinical trials of a number of aromatase inhibitors are
in progress, only the ATAC study assesses the combination of an
British Journal ofCancer (1998) 78(Supplement 4), 12-15 0 Cancer Research Campaign 199814 PE L0nning
aromatase inhibitor (anastrozole) plus tamoxifen in one of the CONCLUSIONS
treatment arms. Tamoxifen levels were found to be reduced when
the agent was administered in combination with the earlier The new potent aromatase inhibitors, such as anastrozole, have
aromatase inhibitor, aminoglutethimide (Lien et al, 1990). Data are proven benefits in the treatment of advanced breast cancer. It is
now available showing that tamoxifen levels are unaffected when hoped that the current trials ofadjuvant treatment with anastrozole
it is co-administered with anastrozole (Dowsett et al, 1998). As a will confirm the benefit of extending the use of these agents to the
result, the two endocrine therapies can be included in combination treatment of early breast cancer in terms of efficacy, tolerability
without compromising the efficacy oftamoxifen. and patient acceptance. This will help to establish their place in the
treatment ofearly breast cancer in post-menopausal women.
Arimidex-Nolvadex (ARNO) trial
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be randomized to receive either anastrozole for 3 years or tamox- (ATAC) adjuvant trial in post-menopausal breast cancer (abstract P99). EurJ
ifen for a further 3 years (Figure 3). The primary assessment Cancer34(suppl. 1): S39 Buzdar A, Jonat W and Howell A (I996a) Anastrozole, a potent and selective
criteria in this study are overall survival, relapse-free survival, aromatase inhibitor, versus megestrol acetate in postmenopausal womenwith
tolerability and quality of life. advanced breast cancer: results ofoverview analysis oftwo phase III trials. J
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of a new drug after 2 years of tamoxifen therapy can prevent the BuzdarAU, Howell A, Jones S, Blomqvist C, Vogel C, Eirman W, WoltersJ,
development of tamoxifen-stimulated tumour progression. In addi- Mauriac L, Eisenberg P, Jonat W, Plourde P and Azab M(1996b) Prolonged
exposure confirms a favorable tolerability profile ofArimidex (anastrozole) as
tion, the benefit of anastrozole in the adjuvant setting will be compared to megestrol acetate (MA) from two large randomised trials in
assessed, taking advantage ofthe demonstrated lack ofcross-resis- postmenopausal women with advanced breast cancer(ABC) (abstract 100).
tance between these drugs in advanced disease. Some patients who ProcAin Soc Clin Oncol 15: 109
may be about to relapse on tamoxifen may benefit from a treat- Buzdar AU, Jones SE.Vogel CL, WolterJ, Plourde P and Webster A (1997) A phase
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